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Abstract  During  the  last  decades,  LDL-apheresis  was 
established as an extracorporeal treatment option for pa-































upon  the  availability  of  highly  efficient  new  drugs  and 
molecular  genetic  approaches  such  as  RNA  silencing  of 
the apoB gene, whereas the liver transplantation and gene 










mon  inherited  metabolic  diseases,  caused  in  most  cases 
by  different  mutations  of  the  LDL  receptor.  Previously, 
this disease in its homozygous form resulted in the early 



























































The  immunoadsorption  of  apolipoprotein  (Apo)  B  is 
based on its binding to immobilized anti-apoB antibodies 



































Year of introduction Procedure Principle LDL-reduction (%) Reference
1966 Plasmapheresis LDL-elimination by plasma exchange [7]
1980 Heparin-adsorption LDL-adsorption (Plasma) [21]
1981 Immunoadsorption LDL-adsorption (Plasma) 35–56 [41]
1983 Differential filtration LDL-filtration (Plasma) 56–62 [51]
1984 Dextran sulfate adsorption LDL-adsorption (Plasma) 49–75 [55]








extracorporeal  LDL  precipitation)  is  one  of  the  standard 
methods of extracorporeal LDL-elimination.
A further technological step in the early 1990s was the 
development  of  a  whole  blood  LDL-apheresis  device, 
named DALI (Direct Adsorption of Lipids), which remo-











































































































After  the  introduction  of  selective  LDL-apheresis,  the 











































































Study (reference) Apheresis patients (n) Reduction of LDL-cholesterol (%) Quantitative angiography (segment-based analysis; %)
NC R P
HELP [36]   51 62 55 30 15
LARS [43]   37 55 49 38 13
GM [52]   25 58 64 < 1 36
FHRS [49]   20 53 65 25 10
LAARS [19]   20 63 45 10 45















































after  single  treatment  which  correspond  to  target  values 
discussed today.
Currently, in Germany, there are two apheresis registers: 
























































































access  similar  to  dialysis  patients  (arteriovenous  fistula), 
which is associated with a certain risk of thrombosis or sepsis.
The combined heart-liver transplantation or liver trans-























































































problems,  progress,  and  perspectives.  International  Archives 
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terolemia:  Japan  low-density  lipoprotein  apheresis  coronary 
















































































koronarer  Herzkrankheit.  Kombination  einer  Plasmatherapie 
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